Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system.

A novel flow-injection chemiluminescence (CL) method for the determination of dihydralazine sulfate (DHZS) is described. The method is based on the reaction of luminol and diperiodatocuprate (K(2)[Cu(H(2)IO(6))(OH)(2)], DPC) in alkaline medium to emit CL, which is greatly enhanced by DHZS. The possible CL mechanism was first proposed based on the kinetic characteristic, CL spectrum and UV spectra. The optimum condition for the CL reaction was in detail studied using flow-injection system. The experiments indicated that under optimum condition, the CL intensity was linearly related to the concentration of DHZS in the range of 7.0x10(-9) to 8.6x10(-7) g mL(-1) with a detection limit (3sigma) of 2.1x10(-9) g mL(-1). The proposed method had good reproducibility with the relative standard deviation 3.1% (n=7) for 5.2x10(-8) g mL(-1) of DHZS. This method has the advantages of simple operation, fast response and high sensitivity. The special advantage of the system is that very low concentration of luminol can react with DPC catalyzed by DHZS to get excellent experiment results. And CL cannot be observed nearly when luminol with same concentration reacts with other oxidants, so luminol-DPC system has higher selectivity than other luminol CL systems. The method has been successfully applied to determine DHZS in serum.

Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis.

A weak chemiluminescence (CL) emission was observed upon mixing peroxynitrite (ONOO(-)) with dihydralazine sulfate (DHZS). Further experiments showed that carbonate media could enhance the CL emission significantly. Based on these observations, a novel flow injection CL method for the determination of DHZS is developed. The CL signal is linearly with DHZS concentration in the range of 0.01-3.0 microg mL(-1) with a detection limit of 3.6 ng mL(-1). The method was applied to the analysis of DHZS in pharmaceutical preparations and compared well with the high-performance liquid chromatography (HPLC) method. The CL mechanism is discussed and it is postulated that it involves nitrosoperoxocarboxylate (ONOOCO(2)(-)), which is an unstable adduct and can rapidly decompose into *NO(2) and *CO(3)(-) radical. The latter can then oxidize DHZS to give out strong CL emission.

Method development for dihydralazine with HPLC-MS/MS--an old but tricky substance in human plasma.

An HPLC-MS/MS method was developed and validated for the determination of dihydralazine in human plasma. HPLC-MS/MS has not been used before in a published paper and provides better sensitivity and selectivity. Therefore a much easier sample preparation than published before is feasible (protein precipitation). As this substance is rather reactive and sensitive some specific care has to be taken hindering the conversion of the substance in whole blood and following human plasma after blood withdrawal. Hydrazines often are used for derivatization of aldehydes and ketones. With specific care (using 1,4-dithiothreitol (DTT) and cooling) dihydralazine can be preserved and analysed without decomposition or conversion in the tested range of 0.500-302 ng/mL of human plasma. The following inter-batch precision and accuracy of the Quality Control Samples resulted: QC-A (1.34 ng/mL plasma) with a precision of coefficient of variation (CV) 7.66% and an accuracy of 103.2%; QC-B (18.2 ng/mL 7.86%, acc. 101.3%); QC-C (258 ng/mL, 9.73%, acc. 98.3%). The inter-batch values of the LLOQ samples at 0.500 ng/mL were 7.17% for CV and accuracy of 106.4%. Mean recovery tested at the QC levels was found to be 103.8%. Specificity in six different plasma samples was good (<10% of the area of the LLOQ). Stability in plasma was tested under different conditions and was sufficient.

Changes in metabolism and blood flow following catecholamine stimulation in the synovial membrane measured with microdialysis.

Adrenergic reactions could mediate metabolic and circulatory changes in the synovial membrane following knee surgery. The interstitial fluid of the synovial membrane and subcutaneous adipose tissue (reference) was monitored in vivo with microdialysis following knee arthroscopy with adrenaline added to the dialysis solvent, adrenaline together with a local anestetic added intra-articularly and without. Local metabolism and blood flow were measured. There was a similar increase, about two fold, in dialysate lactate in all three experimental conditions in the synovial membrane but no change in adipose tissue. Glucose and blood flow decreased by approximately 50% and 10% in both tissues following addition of adrenaline to the dialysate but no changes in the glucose concentrations or blood flow were observed in the other two experimental situations. As regards glycerol the addition of adrenaline caused an approximate 20% increase of the concentration in adipose tissue but an approximate 20% decrease in the synovial membrane. The intra-articular injection caused an approximate 50% increase of the glycerol level in the synovial membrane but no change in adipose glycerol. Thus, the hypermetabolic state in the synovial membrane following standard arthroscopy and the tissue damage (increased glycerol level) in the synovial membrane following postoperative pain relief by intra-articularly injected local anesthetics together with adrenaline doesn't enhance the hypermetabolic state seen postoperatively without adrenaline. However, catecholamines have pronounced in vivo effects on metabolism and blood flow in the synovial membrane.

Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain.

The development of an antibody labeling method with 99mTc is important for cancer imaging. Most bifunctional chelate methods for 99mTc labeling of antibody incorporate a 99mTc chelator through a linkage to lysine residue. In the present study, a novel site-specific 99mTc labeling method at carbohydrate side chain in the Fc region of 2 antibodies (T101 and rabbit anti-human serum albumin antibody (RPAb)) using dihydrazinophthalazine (DHZ) which has 2 hydrazino groups was developed. The antibodies were oxidized with sodium periodate to produce aldehyde on the Fc region. Then, one hydrazine group of DHZ was conjugated with an aldehyde group of antibody through the formation of a hydrazone. The other hydrazine group was used for labeling with 99mTc. The number of conjugated DHZ was 1.7 per antibody. 99mTc labeling efficiency was 46-85% for T101 and 67-87% for RPAb. Indirect labeling with DHZ conjugated antibodies showed higher stability than direct labeling with reduced antibodies. High immunoreactivities were conserved for both indirectly and directly labeled antibodies. A biodistribution study found high blood activity related to directly labeled T101 at early time point as well as low liver activity due to indirectly labeled T101 at later time point. However, these findings do not affect practical use. No significantly different biodistribution was observed in the other organs. The research concluded that DHZ can be used as a site-specific bifunctional chelating agent for labeling antibody with 99mTc. Moreover, 99mTc labeled antibody via DHZ was found to have excellent chemical and biological properties for nuclear medicine imaging.

Spectrophotometric determination of dihydralazine in pharmaceuticals after derivatization with 2-hydroxy-1-naphthaldehyde.

A sensitive and selective colorimetric assay has been developed for the determination of dihydralazine. The method is based on the interaction of dihydralazine with an ethanolic solution of 2-hydroxy-1-naphthaldehyde to yield a water-insoluble yellow product, 1,4-bis[(2-hydroxy-1-naphthyl)methylene hydrazine]phthazine. This colour can be quantified spectrophotometrically at 420 nm. The calibration curve was linear between 0.4 and 8 micrograms ml-1 of dihydralazine. The molar absorptivity at 420 nm is 24000 l mol-1 cm-1. The method was successfully applied to the determination of dihydralazine in mixtures containing other drugs (reserpine, hydrochlorothiazide, oxprenolol, xanthinol, rutoside, chlorthalidone and bietaserpine).